Clinical trial for a new stem-cell based therapy for a rare skin condition proves promising

9 Sep 2015, 4:52 p.m.

Promising findings from a trial for a new stem-cell based therapy for a rare skin condition have been published in the Journal of Investigative Dermatology. The study, which involved intravenous injections of stem-cells, has led to an improvement in the quality of life for the subjects and their carers.Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited skin disease which results in the severe blistering of the skin. It is caused by a mutation in the protein, COL7A1, which leads to reduced anchoring of the upper skin layers to deeper tissue. Currently there is no effective cure for this condition.

The clinical trial, which recruited 10 patients with RDEB, was led by Professor John McGrath at Kings College London and BRC-supported Principal Investigator Dr Anna Martinez at GOSH. The patients were followed up for one year following the stem cell infusions, which took place three times over a six month period. Questionnaires revealed an improvement in skin healing following blistering and a reduced pain score after therapy. The severity of the condition has also reported to be lessened.

Overall, the results from this study appear promising. While the patients in this study were not blinded, which the researchers’ state could lead to a positive bias towards the new treatment, patient benefits such as better sleep and reduced caring needs remains a positive from this study.

Read the full press release here.

Young people donate tissue samples to unlock mysteries of arthritis

A new groundbreaking study led by researchers at the University of Birmingham, Great Ormond Street Hospital, University College London and Birmingham Children’s Hospital has revealed important clues into what is driving arthritis in children.

Toddler doing well after receiving newest gene therapy available on NHS

A toddler with a life-limiting and life-threatening rare disease is the youngest to be treated with the newest gene therapy available on the NHS at GOSH.

Genes may help to predict which children will respond well to arthritis treatment

A team of researchers at Great Ormond Street Hospital (GOSH) and University College London (UCL) have identified a set of genes that could be used to help doctors predict which children will respond well to treatment for juvenile idiopathic arthritis.

Making it easier to invest in frontline care

GOSH and UCL have signed a landmark agreement to simplify the commercialisation of any joint research and innovation and ensure any financial proceeds are shared equally.